The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

On January 30th, in a landmark decision that could reshape the way acute pain is treated in the United States, the FDA approved suzetrigine (brand name, Journavx), a first-in-class non-opioid ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its ...

Dr. Reshma Kewalramani says she was destined to love science and medicine, raised by parents who always dreamed she would ...

(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected ...

In addition to strengthening its cystic fibrosis portfolio, Vertex is also diversifying its pipeline. The FDA’s January 2025 approval of Journavx (suzetrigine), a non-opioid oral pain treatment, ...